{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Moreover, a placebo control is ideal for characterizing the efficacy and safety of an experimental', 'agent in a new study population.', '1.6.', 'Compliance Statement', 'This study will be conducted in full accordance with the International Council for Harmonisation', '(ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP) E6 and any applicable', 'national and local laws and regulations (eg, Title 21 Code of Federal Regulations [21CFR]', 'Parts 11, 50, 54, 56, 312, and 314, Directive 2001/20/EC of the European Parliament and of the', 'Council on the approximation of the laws, regulations, and administrative provisions of the', 'Member States relating to the implementation of GCP in the conduct of clinical studies on', 'medicinal products for human use). Any episode of noncompliance will be documented.', 'The investigator is responsible for performing the clinical study in accordance with this protocol', 'and the applicable GCP guidelines referenced above for collecting, recording, and reporting the', 'data accurately and properly. Agreement of the investigator to conduct and administer this', 'clinical study in accordance with the protocol will be documented in separate clinical study', 'agreements with the sponsor and other forms as required by national competent authorities in the', 'country where each investigational center is located.', 'The investigator is responsible for ensuring the privacy, health, and welfare of the patients during', 'and after the clinical study and must ensure that trained personnel are immediately available in', 'the event of a medical emergency. The investigator and the involved clinical study personnel', 'must be familiar with the background and requirements of the study and with the properties of', 'the IMP as described in the IB.', 'The principal investigator at each investigational center has the overall responsibility for the', 'conduct and administration of the clinical study at that investigational center and for contacts', 'with study management, with the Independent Ethics Committee/Institutional Review Board', '(IEC/IRB), and with competent authorities.', '1.7.', 'Study Population and Justification', 'The population to be studied includes children and adolescents, 6 through 16 years of age, with', \"TS. Per selection criteria, the participants' tics need to be troublesome and cause distress or\", 'impairment based on the assessment of the patient, parent/guardian, and investigator. Based on', 'these criteria, this is a study population in need of treatment.', '1.8.', 'Location and Study Duration', 'This study is planned to be conducted in North America, Russia, and Europe, at approximately', '50 centers. It is expected to start in January 2018 and have a duration of approximately', '15 months. Additional centers will be added, if needed. Expected duration of the study may also', 'be extended dependent on enrollment and other factors.', '39']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '2.', 'PURPOSE OF THE STUDY AND STUDY OBJECTIVES', '2.1.', 'Purpose of the Study', 'This is a Phase 2/3 study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717)', 'tablets for the reduction of motor and phonic tics associated with TS in children and adolescents', '6 through 16 years of age.', '2.2.', 'Study Objectives', '2.2.1.', 'Primary Objective', 'The primary objective of this study is to evaluate the efficacy of TEV-50717 to reduce motor and', 'phonic tics associated with TS.', '2.2.2.', 'Secondary Objective', 'The secondary objective of the study is to evaluate the safety and tolerability of titration and', 'maintenance therapy with TEV-50717.', '2.3.', 'Study Enppoints', '2.3.1.', 'Primary Efficacy Endpoint', 'The primary efficacy endpoint is the change in the TTS of the YGTSS from baseline to week 12.', '2.3.2.', 'Key Secondary Efficacy Enppoints', 'The key secondary efficacy endpoints are as follows:', '1. Change in the TS-CGI score from baseline to week 12', '2. Change in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) score', 'from baseline to week 12', '3. Change in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life', '(C&A-GTS-QOL) activities of daily living (ADL) subscale score from baseline to', 'week 12', '2.3.3.', 'Exploratory Enppoints', 'Exploratory endpoints are as follows:', '40']\n\n###\n\n", "completion": "END"}